Zoetis, Inc. (ZTS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1163150,
    "name": "Zoetis, Inc.",
    "stock_name": "Zoetis, Inc.",
    "full_name": "Zoetis, Inc.",
    "name_url": "stocks-analysis/zoetis-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "120.41",
    "chg": -2.16,
    "chgp": "-1.76%",
    "dir": -1,
    "prev_price": "122.57",
    "mcapval": "71,580.57",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US98978V1035",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "9.88 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/zoetis-inc-1163150-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Zoetis, Inc. Stock Plummets to New 52-Week Low of $122.00",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zoetis-inc-stock-plummets-to-new-52-week-low-of-12200-3674028",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZoetisInc_priceRelatedfactors_3674028.png",
        "date": "2025-11-05 16:44:12",
        "description": "Zoetis, Inc. has reached a new 52-week low, reflecting a 30.4% decline over the past year, contrasting with the S&P 500's positive performance. The company, with a market cap of USD 71,581 million, features a P/E ratio of 31.00 and a dividend yield of 60.56%."
      },
      {
        "title": "Is Zoetis, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zoetis-inc-overvalued-or-undervalued-3637768",
        "imagepath": "",
        "date": "2025-10-21 12:08:34",
        "description": "As of 17 October 2025, the valuation grade for Zoetis, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 31, a Price to Book Value of 17.32, and an EV to EBITDA of 21.76. In comparison, Eli Lilly & Co. has a higher P/E of 40.89, while Johnson & Johnson shows a lower P/E of 26.18, indicating that Zoetis is positioned competitively within its peer group.\n\nDespite the fair valuation, Zoetis has underperformed relative to the S&P 500, with a year-to-date return of -11.58% compared to the S&P 500's 13.30%. This trend continues over longer periods, with a 5-year return of -11.92% against the S&P 500's impressive 91.29%, suggesting that while the stock may be fairly valued, it faces significant challenges in generating returns compared to broader market benchmarks...."
      },
      {
        "title": "Zoetis, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zoetis-changes-valuation-grade-from-expensive-to-fair-amidst-price-fluctuations-3641030",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ZoetisInc_valuationdot_3641030.png",
        "date": "2025-10-20 17:11:21",
        "description": "Zoetis, Inc. has recently adjusted its valuation, with a current P/E ratio of 31 and strong financial metrics, including a return on capital employed of 36.14% and a return on equity of 55.54%. The company remains competitive within the Pharmaceuticals & Biotechnology sector despite recent performance challenges."
      },
      {
        "title": "Is Zoetis, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zoetis-inc-overvalued-or-undervalued-3634638",
        "imagepath": "",
        "date": "2025-10-20 12:25:59",
        "description": "As of 17 October 2025, the valuation grade for Zoetis, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 31, an EV to EBITDA of 21.76, and a PEG ratio of 3.69. In comparison, Eli Lilly & Co. has a higher P/E ratio of 40.89, while Johnson & Johnson shows a lower P/E of 26.18, indicating that Zoetis is positioned reasonably within its peer group.\n\nDespite its fair valuation, Zoetis has underperformed relative to the S&P 500, with a year-to-date return of -11.58% compared to the index's 13.30%. This trend is further emphasized by a five-year return of -11.92% for Zoetis versus the S&P 500's impressive 91.29%, suggesting that while the stock may be fairly valued, it has not delivered strong returns relative to broader market performance...."
      },
      {
        "title": "Is Zoetis, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zoetis-inc-overvalued-or-undervalued-3632177",
        "imagepath": "",
        "date": "2025-10-19 12:03:35",
        "description": "As of 17 October 2025, the valuation grade for Zoetis, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 31, an EV to EBITDA of 21.76, and a PEG ratio of 3.69, which suggest that while the company is priced at a premium, it may still offer reasonable growth potential compared to its earnings.\n\nIn comparison to peers, Zoetis has a P/E ratio of 27.30, which is more attractive than Eli Lilly & Co. at 40.89 but less favorable than Johnson & Johnson at 26.18. The EV to EBITDA ratio for Zoetis is also higher than that of AbbVie, Inc. at 16.51, indicating a relative overvaluation in terms of enterprise value compared to earnings before interest, taxes, depreciation, and amortization. Notably, Zoetis has underperformed against the S&P 500 over multiple periods, with a YTD return of -11.58% compared to the index's 13.30%, re..."
      },
      {
        "title": "Zoetis Adjusts Valuation Grade, Signaling Strong Financial Performance and Investor Interest",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/zoetis-receives-upgrade-to-strong-buy-amid-improved-valuation-and-strong-financial-metrics-3600306",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ZoetisInc_mojoScore_3600306.png",
        "date": "2025-10-07 20:24:10",
        "description": "Zoetis, Inc. has recently experienced a valuation grade adjustment, reflecting a more favorable assessment of its financial metrics and market position. The company demonstrates strong performance indicators, including a competitive P/E ratio, efficient management, and consistent sales growth, attracting significant institutional interest."
      },
      {
        "title": "Zoetis, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zoetis-changes-valuation-grade-from-fair-to-attractive-amidst-price-fluctuations-3595460",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ZoetisInc_valuationdot_3595460.png",
        "date": "2025-10-06 16:10:39",
        "description": "Zoetis, Inc. has recently adjusted its valuation, with its current price at $146.42. Over the past year, the company has seen a 23.34% decline, contrasting with the S&P 500's gains. Key metrics include a P/E ratio of 31 and a strong return on equity of 55.54%."
      },
      {
        "title": "Is Zoetis, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zoetis-inc-overvalued-or-undervalued-3591430",
        "imagepath": "",
        "date": "2025-10-05 11:15:35",
        "description": "As of 3 October 2025, the valuation grade for Zoetis, Inc. has moved from fair to attractive, indicating a more favorable assessment of its market position. The company appears to be undervalued, particularly when considering its P/E ratio of 31, which is higher than the industry average of 27.30, and its EV to EBITDA ratio of 21.76, which also exceeds the peer average. Additionally, Zoetis boasts a robust ROE of 55.54%, suggesting strong profitability relative to shareholder equity.\n\nIn comparison to peers, Eli Lilly & Co. has a P/E ratio of 40.89, while Johnson & Johnson stands at 26.18, highlighting that Zoetis is competitively priced despite its higher valuation ratios. Notably, the stock has underperformed against the S&P 500 over multiple periods, with a 1Y return of -23.34% compared to the index's 17.82%, reinforcing the notion that the stock may be undervalued relative to its potential...."
      },
      {
        "title": "Zoetis Stock Hits Day High with Strong 3.68% Intraday Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zoetis-stock-hits-day-high-with-strong-368-intraday-performance-3585879",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ZoetisInc_priceRelatedfactors_3585879.png",
        "date": "2025-10-01 16:14:06",
        "description": "Zoetis, Inc. has seen a significant rise in stock performance, reaching an intraday high and demonstrating strong market interest. The company maintains a high return on capital employed and a low debt to EBITDA ratio, while also reporting consistent profit growth and robust operating cash flow. Its market capitalization remains substantial."
      }
    ],
    "total": 18,
    "sid": "1163150",
    "stock_news_url": "https://www.marketsmojo.com/news/zoetis-inc-1163150"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Zoetis, Inc. Stock Plummets to New 52-Week Low of $122.00

2025-11-05 16:44:12

Zoetis, Inc. has reached a new 52-week low, reflecting a 30.4% decline over the past year, contrasting with the S&P 500's positive performance. The company, with a market cap of USD 71,581 million, features a P/E ratio of 31.00 and a dividend yield of 60.56%.

Is Zoetis, Inc. overvalued or undervalued?

2025-10-21 12:08:34

As of 17 October 2025, the valuation grade for Zoetis, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 31, a Price to Book Value of 17.32, and an EV to EBITDA of 21.76. In comparison, Eli Lilly & Co. has a higher P/E of 40.89, while Johnson & Johnson shows a lower P/E of 26.18, indicating that Zoetis is positioned competitively within its peer group. Despite the fair valuation, Zoetis has underperformed relative to the S&P 500, with a year-to-date return of -11.58% compared to the S&P 500's 13.30%. This trend continues over longer periods, with a 5-year return of -11.92% against the S&P 500's impressive 91.29%, suggesting that while the stock may be fairly valued, it faces significant challenges in generating returns compared to broader market benchmarks....

Zoetis, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape

2025-10-20 17:11:21

Zoetis, Inc. has recently adjusted its valuation, with a current P/E ratio of 31 and strong financial metrics, including a return on capital employed of 36.14% and a return on equity of 55.54%. The company remains competitive within the Pharmaceuticals & Biotechnology sector despite recent performance challenges.

Is Zoetis, Inc. overvalued or undervalued?

2025-10-20 12:25:59

As of 17 October 2025, the valuation grade for Zoetis, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 31, an EV to EBITDA of 21.76, and a PEG ratio of 3.69. In comparison, Eli Lilly & Co. has a higher P/E ratio of 40.89, while Johnson & Johnson shows a lower P/E of 26.18, indicating that Zoetis is positioned reasonably within its peer group. Despite its fair valuation, Zoetis has underperformed relative to the S&P 500, with a year-to-date return of -11.58% compared to the index's 13.30%. This trend is further emphasized by a five-year return of -11.92% for Zoetis versus the S&P 500's impressive 91.29%, suggesting that while the stock may be fairly valued, it has not delivered strong returns relative to broader market performance....

Is Zoetis, Inc. overvalued or undervalued?

2025-10-19 12:03:35

As of 17 October 2025, the valuation grade for Zoetis, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 31, an EV to EBITDA of 21.76, and a PEG ratio of 3.69, which suggest that while the company is priced at a premium, it may still offer reasonable growth potential compared to its earnings. In comparison to peers, Zoetis has a P/E ratio of 27.30, which is more attractive than Eli Lilly & Co. at 40.89 but less favorable than Johnson & Johnson at 26.18. The EV to EBITDA ratio for Zoetis is also higher than that of AbbVie, Inc. at 16.51, indicating a relative overvaluation in terms of enterprise value compared to earnings before interest, taxes, depreciation, and amortization. Notably, Zoetis has underperformed against the S&P 500 over multiple periods, with a YTD return of -11.58% compared to the index's 13.30%, re...

Zoetis Adjusts Valuation Grade, Signaling Strong Financial Performance and Investor Interest

2025-10-07 20:24:10

Zoetis, Inc. has recently experienced a valuation grade adjustment, reflecting a more favorable assessment of its financial metrics and market position. The company demonstrates strong performance indicators, including a competitive P/E ratio, efficient management, and consistent sales growth, attracting significant institutional interest.

Zoetis, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

2025-10-06 16:10:39

Zoetis, Inc. has recently adjusted its valuation, with its current price at $146.42. Over the past year, the company has seen a 23.34% decline, contrasting with the S&P 500's gains. Key metrics include a P/E ratio of 31 and a strong return on equity of 55.54%.

Is Zoetis, Inc. overvalued or undervalued?

2025-10-05 11:15:35

As of 3 October 2025, the valuation grade for Zoetis, Inc. has moved from fair to attractive, indicating a more favorable assessment of its market position. The company appears to be undervalued, particularly when considering its P/E ratio of 31, which is higher than the industry average of 27.30, and its EV to EBITDA ratio of 21.76, which also exceeds the peer average. Additionally, Zoetis boasts a robust ROE of 55.54%, suggesting strong profitability relative to shareholder equity. In comparison to peers, Eli Lilly & Co. has a P/E ratio of 40.89, while Johnson & Johnson stands at 26.18, highlighting that Zoetis is competitively priced despite its higher valuation ratios. Notably, the stock has underperformed against the S&P 500 over multiple periods, with a 1Y return of -23.34% compared to the index's 17.82%, reinforcing the notion that the stock may be undervalued relative to its potential....

Zoetis Stock Hits Day High with Strong 3.68% Intraday Performance

2025-10-01 16:14:06

Zoetis, Inc. has seen a significant rise in stock performance, reaching an intraday high and demonstrating strong market interest. The company maintains a high return on capital employed and a low debt to EBITDA ratio, while also reporting consistent profit growth and robust operating cash flow. Its market capitalization remains substantial.

View All News